MTORC MODULATORS AND USES THEREOF
DE602020073271T2Active Publication Date: 2026-06-10AEOVIAN PHARMACEUTICALS INC BERKELEY
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602020073271
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-01-22
- Filing Date
- 2020-01-22
- Publication Date
- 2026-06-10
- Estimated Expiration
- 2040-01-22
AI Technical Summary
Technical Problem
Rapamycin's therapeutic potential is limited by its prohibitive safety profile, including adverse effects such as peripheral edema, hypercholesterolemia, and impaired insulin sensitivity, which are primarily due to the inhibition of mTORC2, while mTORC1 inhibition is responsible for lifespan extension.
Method used
Development of rapamycin analogs (rapalogs) that selectively inhibit mTORC1 with minimal inhibition of mTORC2, represented by a specific structural formula, to treat chronic diseases.
Benefits of technology
The rapalogs provide therapeutic benefits by reducing adverse effects and enhancing treatment efficacy for diseases like neurodegenerative disorders, cancer, and metabolic diseases, while minimizing mTORC2-related side effects.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.